Additionally, Genmab announced that AbbVie (NYSE: ABBV) submitted a Marketing Authorization Application (MAA) for epcoritamab for the treatment of patients with relapsed/refractory diffuse large ...
Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 ...
Breyanzi has the potential to be the first and only CAR T cell therapy approved for MZL, addressing a high unmet need Application based on results from MZL cohort of TRANSCEND FL presented at ICML in ...
BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that they have submitted a Marketing Authorisation Application (MAA) to the European ...
Moldables and refractory cement are very important for many industries. In the construction of large ovens and furnaces, where refractory linings or high-temperature firebricks are present, castable ...
NORTH CHICAGO, Ill., Oct. 28, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results